Ensure adequate calorie intake. To ensure that Aminefron is used anabolically, patients should take 150-170 kJ (35-40 kCal/kg body weight/day).
In accordance with the improvement of uremic symptoms with the use of Aminefron, the administration of aluminium hydroxide should be reduced.
Calcium: 1 film-coated caplet contains 50 mg of calcium. Aminefron may lead to hypercalcemia, especially when Aminefron is administered >25 times daily or in concomitant use with other calcium-containing drugs (ie, ion-exchange in hypercalcemia therapy) or simultaneous administration of antacids. The possibility of hypercalcemia should be considered in this case. Therefore, it is advisable to check serum calcium levels on a regular basis.
Aminefron is not recommended in concomitant use with drugs that can perform combination solution with calcium (eg, tetracycline).
Use in pregnancy & lactation: Use in pregnant and nursing women should be avoided as clinical data is inadequate.
Use in children: Use in children should be avoided as clinical data is inadequate.